PANK-003 Cell Injection Combined With Standard Adjuvant Chemotherapy After Surgery in Patients With Stage IIIA NSCLC

Inclusion Criteria:

1. Voluntarily participate in the clinical trial; fully understand and be informed about this study and sign the informed consent form;
2. At the time of screening, the age should be between 18 and 75 years old (inclusive), regardless of gender;
3. Patients with histologically confirmed stage IIIA NSCLC (T4N0M0, T3-4N1M0, T1a-2bN2M0) who underwent R0 resection and received postoperative adjuvant chemotherapy (Exclusion of EGFR sensitizing mutations and ALK fusion); and who received the first dose of PANK-003 cell injection combined with postoperative adjuvant chemotherapy within 8 weeks after radical surgery.;
4. At the time of enrollment, the expected survival time is more than 6 Months;
5. The Eastern Cooperative Oncology Group (ECOG) performance status score is 0 or 1;
6. At the time of screening, the laboratory tests should meet the following requirements:

   * White blood cell count ≥ 3.0×10⁹/L;
   * Neutrophil count ≥ 1.5×10⁹/L;
   * Lymphocyte count ≥ 0.5×10⁹/L;
   * Hemoglobin ≥ 90 g/L;
   * Platelets ≥ 75×10⁹/L;
   * Serum total bilirubin ≤ 2.0 × ULN (Upper Limit of Normal); for patients with a history/suspected Gilbert's syndrome, total bilirubin (TBIL) must be ≤ 3 × ULN.
   * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5× ULN;
   * Creatinine \< 1.5×ULN and endogenous creatinine clearance rate ≥ 50 mL/minute (Cockcroft-Gault method for calculating creatinine clearance rate: For men, creatinine clearance rate = \[(140 - age) × body weight (kg)\] / \[0.818 × creatinine (μmol/L)\]; For women, creatinine clearance rate = \[(140 - age) × body weight (kg) × 0.85\] / \[0.818 × creatinine (μmol/L)\]).
7. Female subjects of childbearing potential must have a negative serum pregnancy test at screening and be willing to use medically recognized highly effective contraception during the study and for at least 1 year after the last study treatment; male subjects with partners of childbearing potential must have undergone surgical sterilization or agree to use effective contraception during the study and for at least 1 year after the last study treatment;
8. Investigator-confirmed eligibility for study enrollment.

Exclusion Criteria:

1. NSCLC patients who have received neoadjuvant therapy;
2. Pregnant or lactating women;
3. History of other malignancies, except:

   * Cured non-melanoma skin cancer
   * Carcinoma in situ of the cervix
   * Localized prostate cancer
   * Superficial bladder cancer
   * Other malignancies with disease-free survival \>5 years;
4. Positive virology serology meeting any of:

   * HBsAg(+) and/or HBeAg(+) with HBe-Ab(+) and/or HBc-Ab(+) and HBV-DNA \> lower limit of quantification
   * HCV-Ab(+)
   * TP-Ab(+)
   * HIV-Ab(+);
5. Received investigational drugs or other cell-based immunotherapy within 28 days before screening;
6. Administration of live/attenuated vaccines within 4 weeks prior to NK cell infusion;
7. Medical conditions requiring systemic corticosteroid therapy or other immunosuppressive drug treatments during the study period as determined by the investigator;
8. Hypersensitivity to:

   * Any component of NK cell products (including serum albumin)
   * Common emergency medications or anesthetics;
9. Unstable cardiovascular diseases within 180 days pre-screening, including:

   * Unstable angina
   * Myocardial infarction
   * Heart failure (NYHA class ≥III)
   * Severe arrhythmia requiring medication
   * Cardiac angioplasty, coronary stenting, or CABG;
10. Any condition that may compromise protocol compliance or patient safety as determined by the investigator:

    * Poorly controlled diabetes
    * Uncontrolled infections
    * Central nervous system disorders
    * Bleeding/thrombotic diathesis
    * Poor compliance
    * Substance abuse.